The role of clopidogrel in revascularized and nonrevascularized patients with acute coronary syndromes

American Journal of Cardiovascular Drugs

Volumn 7, Issue 3, 2007, Pages 159-168

  Collins, J Stewart ^a   Gurm, Hitinder S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; CYCLIC AMP; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; METOPROLOL; PADGEM PROTEIN; PURINE P2X RECEPTOR; PURINE P2Y RECEPTOR; STREPTOKINASE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ANGIOGENESIS; ARTERY DISEASE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG USE; HEALTH CARE COST; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; ST SEGMENT ELEVATION; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS; VASCULARIZATION;

ACUTE DISEASE; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; GUIDELINE ADHERENCE; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES; TICLOPIDINE;

EID: 34447255875     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200707030-00002     Document Type: Review

References (52)

1. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics, 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006 Feb 14; 113 (6): e85-151
2. Gurm H, Topol EJ. Definitions of acute coronary syndromes. In: Fuster V, Nabel E, Topol EJ, editors. Atherosclerosis and coronary artery disease. 2nd ed. Philadelphia (PA): Lippincott-Williams and Wilkins, 2004
3. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease: the RISC Group. Lancet 1990 Oct 6; 336 (8719): 827-30
4. Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients: Antiplatelet Trialists' Collaboration. BMJ 1994 Jan 8; 308 (6921): 81-106
5. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988 Oct 27; 319 (17): 1105-11
6. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001 Jun 21; 344 (25): 1879-87
7. Wallentin L, Lagerqvist B, Husted S, et al., on behalf of the FRISC II Investigators. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. Fast revascularisation during instability in coronary artery disease. Lancet 2000 Jul 1; 356 (9223): 9-16
8. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998 May 21; 338 (21): 1498-505
9. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998 Aug 13; 339 (7): 436-43
10. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001 Jun 16; 357 (9272): 1915-24
11. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001 Aug 18; 358 (9281): 527-33
12. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001 Aug 16; 345 (7): 494-502
13. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002 Oct 2; 40 (7): 1366-74
14. Steinhubl SR, Berger PB, Mann III JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002 Nov 20; 288 (19): 2411-20
15. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004 Aug 3; 110 (5): 588-636
16. Smith Jr SC, Feldman TE, Hirshfeld Jr JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006 Feb 21; 113 (7): e166-286
17. Schulman SP. Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes. JAMA 2004 Oct 20; 292 (15): 1875-82
18. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999 Oct 12; 100 (15): 1667-72
19. Gachet C, Hechler B. The platelet P2 receptors in thrombosis. Semin Thromb Hemost 2005 Apr; 31 (2): 162-7
20. Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des 2006; 12 (10): 1255-9
21. Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005 Apr; 31 (2): 174-83
22. Plavix package insert prescribing information. New York: Bristol-Meyers-Squibb/Sanofi Pharmaceuticals, 2006
23. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996 Nov 16; 348 (9038): 1329-39
24. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998 Dec 3; 339 (23): 1665-71
25. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996 Apr 25; 334 (17): 1084-9
26. Steinhubl SR, Ellis SG, Wolski K, et al. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation 2001 Mar 13; 103 (10): 1403-9
27. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006 Apr 20; 354 (16): 1706-17
28. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005 Mar 24; 352 (12): 1179-89
29. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005 Sep 14; 294 (10): 1224-32
30. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005 Nov 5; 366 (9497): 1607-21
31. Lewis BS, Mehta SR, Fox KA, et al. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Am Heart J 2005 Dec; 150 (6): 1177-84
32. Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004 Sep 7; 110 (10): 1202-8
33. Mehta RH, Chen AY, Pollack Jr CV, et al. Challenges in predicting the need for coronary artery bypass grafting at presentation in patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol 2006 Sep 1; 98 (5): 624-7
34. Dogan A, Ozgul M, Ozaydin M, et al. Effect of clopidogrel plus aspirin on tissue perfusion and coronary flow in patients with ST-segment elevation myocardial infarction: a new reperfusion strategy. Am Heart J 2005 Jun; 149 (6): 1037-42
35. Krumholz HM, Anderson JL, Brooks NH, et al. ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-Elevation Myocardial Infarction). Circulation. 2006 Feb 7; 113 (5): 732-61
36. Peterson ED, Roe MT, Mulgund J, et al. Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA 2006 Apr 26; 295 (16): 1912-20
37. Ohman EM, Roe MT, Smith Jr SC, et al. Care of non-ST-segment elevation patients: insights from the CRUSADE national quality improvement initiative. Am Heart J 2004 Nov; 148 (5 Suppl. 1): S34-9
38. Eagle KA, Montoye CK, Riba AL, et al. Guideline-based standardized care is associated with substantially lower mortality in medicare patients with acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice (GAP) Projects in Michigan. J Am Coll Cardiol 2005 Oct 4; 46 (7): 1242-8
39. Mehta RH, Montoye CK, Faul J, et al. Enhancing quality of care for acute myocardial infarction: shifting the focus of improvement from key indicators to process of care and tool use: the American College of Cardiology Acute Myocardial Infarction Guidelines Applied in Practice Project in Michigan. Flint and Saginaw expansion. J Am Coll Cardiol 2004 Jun 16; 43 (12): 2166-73
40. Tricoci P, Roe MT, Mulgund J, et al. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med 2006 Apr 10; 166 (7): 806-11
41. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006 Jun 20; 113 (24): 2803-9
42. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005 May 4; 293 (17): 2126-30
43. Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006 Feb 28; 113 (8): 1108-13
44. Herper M, Kang P. The world's top ten selling drugs: 2005 [online]. Available from URL: http://www.forbes.com/2006/03/21/pfizer-merck-amgen- cx_mh_pk_0321topdrugs.html [Accessed]
45. Beinart SC, Kolm P, Veledar E, et al. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J Am Coll Cardiol 2005 Sep 6; 46 (5): 761-9
46. Mahoney EM, Mehta S, Yuan Y, et al. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am Heart J 2006 Jan; 151 (1): 219-27
47. Weintraub WS, Mahoney EM, Lamy A, et al. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol 2005 Mar 15; 45 (6): 838-45
48. Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med 2005 Feb 15; 142 (4): 251-9
49. Lyseng-Williamson KA, Plosker GL. Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes. Pharmacoeconomics 2006; 24 (7): 709-26
50. Main C, Palmer S, Griffin S, et al. Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. Health Technol Assess 2004 Oct; 8 (40): iii-iv, xv-xvi, 1-141
51. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003 Oct 7; 108 (14): 1682-7
52. Mehta RH, Roe MT, Mulgund J, et al. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. J Am Coll Cardiol 2006 Jul 18; 48 (2): 281-6